Compare NXDT & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXDT | VNDA |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 286.8M | 301.1M |
| IPO Year | 2006 | 2005 |
| Metric | NXDT | VNDA |
|---|---|---|
| Price | $5.26 | $4.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 131.9K | ★ 623.3K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 9.66% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $85,965,000.00 | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.30 | ★ 8.72 |
| 52 Week Low | $2.55 | $4.27 |
| 52 Week High | $5.95 | $9.91 |
| Indicator | NXDT | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 41.35 |
| Support Level | $5.20 | $4.94 |
| Resistance Level | $5.54 | $5.62 |
| Average True Range (ATR) | 0.15 | 0.16 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 40.13 | 10.68 |
NexPoint Diversified Real Estate Trust is an externally advised REIT focused on the acquisition, asset management, development, and disposition of opportunistic, value-add investments in real estate properties throughout the United States. The company has two reportable segments: The Diversified reportable segment is focused on investing in various commercial real estate property types and across the capital structure, including but not limited to, equity, mortgage, debt, mezzanine debt and preferred equity. The Hospitality segment is focused on operating and renovating its U.S. located hospitality assets that meet its investment objective and criteria. Its Portfolio includes investments in the single-family rental, self-storage, office, hospitality, life science and multifamily sectors.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.